18F-FDG PET in evaluating patients treated for metastatic colorectal cancer: Can we predict prognosis?

Journal of Nuclear Medicine

Volumn 45, Issue 9, 2004, Pages 1428-1430

  Metser, Ur ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GLUCOSE; OXALIPLATIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME; WEIGHT CHANGE; ALGORITHM; COLORECTAL TUMOR; COMPUTER ASSISTED DIAGNOSIS; DISEASE FREE SURVIVAL; METHODOLOGY; MORTALITY; NOTE; RISK ASSESSMENT; RISK FACTOR; SCINTISCANNING; SURVIVAL; TREATMENT OUTCOME;

ALGORITHMS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 6944239796     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer. 2000;82:1789-1794.
2. 18F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784-1788.
3. Guillem JG, Puig-La Calle J Jr, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000;43:18-24.
4. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492-499.
5. Findlay M, Young H, Cunningham D, et al. Non-invasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-708.
6. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897-916.
7. Gupta N, Harmindar G, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998;114:1105-1111.
8. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med. 2001;42:713-720.
9. Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology. 1999;211:249-256.
10. 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480-1487.
11. Dimitrakopoulou-Strauss A, Strauss LG, Mikolajczyk K, et al. On the fractal nature of positron emission tomography (PET) studies. World J Nucl Med. 2003;4:306-313.
12. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Intravenous and intra-arterial oxygen-15-labeled water and fluorine18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med. 1998;39:465-473.
13. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med. 2003;47:8-13.